Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ovarian cancer mutational processes drive site-specific immune evasion.
Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP. Vázquez-García I, et al. Among authors: nikolovski i. Nature. 2022 Dec;612(7941):778-786. doi: 10.1038/s41586-022-05496-1. Epub 2022 Dec 14. Nature. 2022. PMID: 36517593 Free PMC article.
Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
Kumar A, Sheedy S, Kim B, Suidan R, Sarasohn DM, Nikolovski I, Lakhman Y, McGree ME, Weaver AL, Chi D, Cliby WA. Kumar A, et al. Among authors: nikolovski i. Gynecol Oncol. 2019 Jul;154(1):72-76. doi: 10.1016/j.ygyno.2019.04.011. Epub 2019 Apr 16. Gynecol Oncol. 2019. PMID: 31000471 Free PMC article.
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
Jiménez-Sánchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier DL, Memon D, Selenica P, Nikolovski I, Mazaheri Y, Bykov Y, Geyer FC, Macintyre G, Gavarró LM, Drews RM, Gill MB, Papanastasiou AD, Sosa RE, Soslow RA, Walther T, Shen R, Chi DS, Park KJ, Hollmann T, Reis-Filho JS, Markowetz F, Beltrao P, Vargas HA, Zamarin D, Brenton JD, Snyder A, Weigelt B, Sala E, Miller ML. Jiménez-Sánchez A, et al. Among authors: nikolovski i. Nat Genet. 2020 Jun;52(6):582-593. doi: 10.1038/s41588-020-0630-5. Epub 2020 Jun 1. Nat Genet. 2020. PMID: 32483290 Free PMC article.
A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Straubhar AM, Filippova OT, Cowan RA, Lakhman Y, Sarasohn DM, Nikolovski I, Torrisi JM, Ma W, Abu-Rustum NR, Gardner GJ, Sonoda Y, Zivanovic O, Chi DS, Long Roche K. Straubhar AM, et al. Among authors: nikolovski i. Gynecol Oncol. 2020 Sep;158(3):608-613. doi: 10.1016/j.ygyno.2020.05.041. Epub 2020 Jun 6. Gynecol Oncol. 2020. PMID: 32518012 Free PMC article.
Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers.
Veeraraghavan H, Friedman CF, DeLair DF, Ninčević J, Himoto Y, Bruni SG, Cappello G, Petkovska I, Nougaret S, Nikolovski I, Zehir A, Abu-Rustum NR, Aghajanian C, Zamarin D, Cadoo KA, Diaz LA Jr, Leitao MM Jr, Makker V, Soslow RA, Mueller JJ, Weigelt B, Lakhman Y. Veeraraghavan H, et al. Among authors: nikolovski i. Sci Rep. 2020 Oct 20;10(1):17769. doi: 10.1038/s41598-020-72475-9. Sci Rep. 2020. PMID: 33082371 Free PMC article.
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Rubinstein MM, Grisham RN, Cadoo K, Kyi C, Tew WP, Friedman CF, O'Cearbhaill RE, Zamarin D, Zhou Q, Iasonos A, Nikolovski I, Xu H, Soldan KN, Caird I, Martin M, Guillen J, Eid KT, Aghajanian C, Makker V. Rubinstein MM, et al. Among authors: nikolovski i. Gynecol Oncol. 2021 Jan;160(1):71-76. doi: 10.1016/j.ygyno.2020.10.019. Epub 2020 Nov 1. Gynecol Oncol. 2021. PMID: 33139041 Free PMC article. Clinical Trial.
21 results